Investigating a new treatment for substance use disorders using a novel drug
Official title: Determination of Route of Administration and Cardiac Safety of a Novel Psychoplastogen for the treatment of SUDs
Funded at Delix Therapeutics · NIH-10744481 · Data updated 2026-11-12
This study is testing a new medication called DLX-007 to see if it can help people with substance use disorders by improving brain flexibility, and it will explore the best and safest ways to give this treatment, whether through injections or pills.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Delix Therapeutics NIH-funded |
| Lab location | 1 site (Palo Alto, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2025 |
| Funding year | 2023 |
| Award (this year) | $319,313 |
| NIH project number | 1R43DA059054-01 |
| Project ID | NIH-10744481 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with substance use disorders, particularly those who may benefit from new treatment options.
✕Less likely to help
Patients who are not struggling with substance use disorders or those with contraindications to the drug may not receive any benefit from this research.
What this research studies
This research focuses on developing a new class of compounds called psychoplastogens, specifically DLX-007, which aims to enhance neuroplasticity to treat substance use disorders (SUDs). The study will evaluate different methods of administering this drug, including intramuscular and oral routes, while ensuring it is safe for the heart. By examining how the drug behaves in the body through pharmacokinetic studies, the research aims to find the most effective and safe way to deliver this treatment to patients. If successful, this could lead to a new therapeutic option for individuals struggling with addiction.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with substance use disorders.
How similar studies have gone: Previous research on psychoplastogens like Ibogaine and 5-MeO-DMT has shown promising results, suggesting that this approach may be effective.
Where this research is happening
-
Delix Therapeutics
Palo Alto, United States Active
Researchers
- Principal investigator: Mctighe, Stephanie — Delix Therapeutics
- Study coordinator: Mctighe, Stephanie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.